Chaoyang, Liaoning, China In 2010 was created Yanyuan Capital, which is appeared as VC. The leading representative office of defined VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.
We also calculated 1 valuable employee in our database.
The typical case for the fund is to invest in rounds with 6 participants. Despite the Yanyuan Capital, startups are often financed by Qiming Venture Partners, TF Capital. The meaningful sponsors for the fund in investment in the same round are YuanMing Capital, WuXi AppTec, Qiming Venture Partners. In the next rounds fund is usually obtained by Qiming Venture Partners.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight CANbridge Life Sciences. We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The top activity for fund was in 2017. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Athlete Tech Group | Canada, Ontario, Toronto |
| Friedman Fleischer & Lowe (FFL) | California, San Francisco, United States |
| G Square | England, London, United Kingdom |
| MEMC Electronic Materials | Missouri, O Fallon, United States |
| O2 Investment Partners | Bloomfield Hills, Michigan, United States |
| Red Avenue | China, Shanghai |
| Riggs Bank | District of Columbia, United States, Washington |
| VYinli | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Lingdi Technology | $30M | 11 Mar 2021 | - | ||
Asieris Pharmaceuticals | $44M | 28 Jun 2020 | Shanghai, China | ||
Asieris Pharmaceuticals | $15M | 24 Mar 2020 | Shanghai, China | ||
Lingdi Technology | $15M | 12 Feb 2020 | - | ||
Shentong | $1M | 23 Mar 2018 | Yinzhou District, Zhejiang, China | ||
CANbridge Pharmaceuticals | $25M | 23 May 2017 | Dongcheng District, Beijing, China | ||
Tiande Technology | $463K | 24 Apr 2017 | Haidian District, Beijing, China | ||
Feichang Danao | $1M | 06 Aug 2015 | Dongcheng District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Lingdi Technology | $30M | 11 Mar 2021 | - | ||
Asieris Pharmaceuticals | $44M | 28 Jun 2020 | Shanghai, China | ||
Asieris Pharmaceuticals | $15M | 24 Mar 2020 | Shanghai, China | ||
Lingdi Technology | $15M | 12 Feb 2020 | - | ||
Shentong | $1M | 23 Mar 2018 | Yinzhou District, Zhejiang, China | ||
CANbridge Pharmaceuticals | $25M | 23 May 2017 | Dongcheng District, Beijing, China | ||
Tiande Technology | $463K | 24 Apr 2017 | Haidian District, Beijing, China | ||
Feichang Danao | $1M | 06 Aug 2015 | Dongcheng District, Beijing, China |
